Adaptive Biotechnologies Corporation
25.51USD
+1.1000 (+4.51%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on ADPT.
Consensus EPS on the street’s adjusted basis, not the filed GAAP figure — which is why the actuals here can differ from the income statement.
| Period | Consensus EPS | 90 days ago | Revisions up (30d) | Revisions down (30d) |
|---|---|---|---|---|
| Current quarter | -$0.1▲ | -$0.11 | 7 | 0 |
| Next quarter | -$0.06▲ | -$0.08 | 0 | 1 |
| Current year | -$0.54▼ | -$0.45 | 0 | 1 |
| Next year | -$0.18▲ | -$0.24 | 2 | 0 |
Beat in 3 of the last 4
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| 2026-06-30 | -$0.13 | -$0.25 | -0.12 (-87.2%) |
| 2026-03-31 | -$0.16 | -$0.13 | +0.03 (+20.2%) |
| 2025-12-31 | -$0.18 | -$0.09 | +0.09 (+50.8%) |
| 2025-09-30 | -$0.14 | $0.06 | +0.20 (+143.3%) |
80 ratings from 13 firms
Ratings are attributed to the research firm, not to individual analysts. See every ticker.
| Firm | Action | Rating | Price Target | Date |
|---|---|---|---|---|
| TD Cowen | Maintained | Buy | $28 $32 | Oct 13, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $22 $27 | Oct 13, 2026 |
| Guggenheim | Maintained | Buy | $25 $32 | Oct 1, 2026 |
| Goldman Sachs | Initiated | Buy | $35 | Sep 29, 2026 |
| BTIG | Maintained | Buy | $25 $34 | Sep 22, 2026 |
| Piper Sandler | Maintained | Overweight | $20 $27.5 | Aug 4, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $20 $22 | Jul 30, 2026 |
| TD Cowen | Maintained | Buy | $25 $28 | Jul 30, 2026 |
| Guggenheim | Maintained | Buy | $22 $25 | Jul 30, 2026 |
| BTIG | Maintained | Buy | $24 $25 | Jul 30, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $18 $20 | Jul 9, 2026 |
| Guggenheim | Maintained | Buy | $21 $22 | Jun 29, 2026 |
| BTIG | Reiterated | Buy | $22 | Jun 17, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $21 $18 | May 12, 2026 |
| JP Morgan | Maintained | Overweight | $21 $19 | May 6, 2026 |
| TD Cowen | Maintained | Buy | $19 $21 | May 6, 2026 |
| Guggenheim | Reiterated | Buy | $21 | May 6, 2026 |
| BTIG | Reiterated | Buy | $22 | May 6, 2026 |
| JP Morgan | Maintained | Overweight | $20 $21 | Feb 6, 2026 |
| BTIG | Maintained | Buy | $21 $22 | Feb 6, 2026 |
| Guggenheim | Maintained | Buy | $20 $21 | Jan 26, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $11 $16 | Nov 11, 2025 |
| JP Morgan | Maintained | Overweight | $17 $20 | Nov 6, 2025 |
| BTIG | Maintained | Buy | $19 $21 | Nov 6, 2025 |
| BTIG | Maintained | Buy | $14 $19 | Oct 22, 2025 |
222 filings from 13 insiders · 16 buy / 28 sell over 6m
Officers and directors of ADPT, from the last two years of filings. Grants, gifts and option exercises are shown but not colour-coded — they are compensation, not a view on the price.
| Insider | Action | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 21, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 5.9k | $25.57 | $150k | Oct 21, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 6.0k | $25.25 | $151k | Oct 21, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Exercise | 11.9k | $12.14 | $144k | Oct 21, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 20, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 100 | $24.85 | $2k | Oct 20, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 11.8k | $24.53 | $289k | Oct 20, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Exercise | 11.9k | $12.14 | $144k | Oct 20, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 19, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 11.9k | $24.05 | $286k | Oct 19, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Exercise | 11.9k | $12.14 | $144k | Oct 19, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 16, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 300 | $25.45 | $8k | Oct 16, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 11.6k | $24.21 | $280k | Oct 16, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Exercise | 11.9k | $12.14 | $144k | Oct 16, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 15, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 11.9k | $25.61 | $304k | Oct 15, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Exercise | 11.9k | $12.14 | $144k | Oct 15, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | ExerciseStock Option (right to buy) | 11.9k | — | — | Oct 14, 2026 |
| RUBINSTEIN JULIEOfficer, President and COO | Sell | 5.1k | $25.82 | $132k | Oct 14, 2026 |
No analyst notes on ADPT yet.
Analyst Ratings
7 analysts covering
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Consensus |
|---|---|---|---|---|---|---|
| Current | 2 | 6 | 0 | 0 | 0 | Buy1.75 |
| 1 mo ago | 2 | 6 | 1 | 0 | 0 | Buy1.89 |
| 2 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
| 3 mo ago | 2 | 5 | 1 | 0 | 0 | Buy1.88 |
Members whose judged calls on ADPT have played out most reliably.
No settled calls on ADPT yet. Nobody has filed a call with a deadline on it.
A member is listed once they have three judged calls on a name.
A call with a target is judged on whether the price reaches it by the deadline, counting each day's high (a buy) or low (a sell) from the day after the call was made. A call without one is judged on whether the price at the close on the deadline is higher (a buy) or lower (a sell) than the price the call was made at: the live price when it was saved, for a call made with Make a call, or the last close before the day it was filed, for a call made in a note. Not against the market or an index.
A percentage appears once five calls have reached their deadline. A target reached sooner is shown as played out early, and counts toward the percentage when its deadline passes, because a miss cannot be known before then.
A member’s prediction, judged on price history · not investment advice